Omeprazole and Sodium Bicarbonate Powder Packets and Pexidartinib
Determining the interaction of Omeprazole and Sodium Bicarbonate Powder Packets and Pexidartinib and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with proton pump inhibitors (PPIs) may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown. MANAGEMENT: Concomitant use of pexidartinib with proton pump inhibitors should be avoided. If acid-suppression therapy is required, pexidartinib may be administered 2 hours before or 2 hours after taking a locally-acting antacid, or if using an H2-receptor antagonist, administer pexidartinib at least 2 hours before or 10 hours after taking the H2-receptor antagonist. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:GENERALLY AVOID: Coadministration with proton pump inhibitors (PPIs) may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown.
MANAGEMENT: Concomitant use of pexidartinib with proton pump inhibitors should be avoided. If acid-suppression therapy is required, pexidartinib may be administered 2 hours before or 2 hours after taking a locally-acting antacid, or if using an H2-receptor antagonist, administer pexidartinib at least 2 hours before or 10 hours after taking the H2-receptor antagonist.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: omeprazole / sodium bicarbonate
Brand name: Zegerid, Zegerid OTC
Synonyms: Omeprazole and sodium bicarbonate, Omeprazole and Sodium Bicarbonate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Omeprazole and Sodium Bicarbonate Powder Packets-Pexidartinib Hydrochloride
- Omeprazole and Sodium Bicarbonate Powder Packets-Pfizerpen
- Omeprazole and Sodium Bicarbonate Powder Packets-Pharaon Tea
- Omeprazole and Sodium Bicarbonate Powder Packets-Pharmorubicin Pfs
- Omeprazole and Sodium Bicarbonate Powder Packets-Phazyme
- Omeprazole and Sodium Bicarbonate Powder Packets-Phazyme Liquid Gas Relief, Maximum Strength
- Pexidartinib-Omeprazole Delayed-Release Capsules
- Pexidartinib-Omeprazole Delayed-Release Capsules and Tablets (OTC)
- Pexidartinib-Omeprazole Orally-Disintegrating Tablets
- Pexidartinib-Omeprazole Powder for Oral Suspension
- Pexidartinib-Omeprazole Tablets
- Pexidartinib-Omeprazole, Clarithromycin, and Amoxicillin